Carbapenem resistant Enterobacteriaceae - second update
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.
Rapid risk assessment: Regional outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019
A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.
Laboratory manual for carbapenem and colistin resistance detection and characterisation for the survey of carbapenem- and/or colistin-resistant Enterobacteriaceae
This protocol is based partly on the laboratory manual developed for the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE)
Rapid risk assessment: Carbapenemase-producing (OXA-48) Klebsiella pneumoniae ST392 in travellers previously hospitalised in Gran Canaria, Spain
This rapid risk assessment evaluates the risk of transmission and further spread of OXA-48-producing Klebsiella pneumonia e ST392 from travellers having sought medical care in Gran Canaria to healthcare facilities in their country of origin in the EU/EEA.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Rapid risk assessment: Hospital-acquired malaria infections in the European Union
Following the occurrence of several hospital-acquired malaria cases in the European Union (EU), ECDC has assessed the risk related to transmission of the parasite in hospital settings.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
Proposals for EU guidelines on the prudent use of antimicrobials in humans
Proposal for EU guidelines on the prudent use of antimicrobials in human medicine, including generic principles of good practice on the appropriate use of antimicrobial agents in human medical practice in the EU.
Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016
This risk assessment provides an overview of the epidemiological situation in Europe and describes a number of response options.
RRA: Invasive cardiovascular infection by Mycobacterium chimaera associated with the 3T heater-cooler system used during open-heart surgery - 1st update, 21 November 2016
In view of new evidence, ECDC has updated its rapid risk assessment on the potential risk of invasive cardiovascular infection by M. chimaera associated with the use of heater-cooler units.